7 May 2008: NorDiag had operating revenues of NOK 3.4 million and other revenues of NOK 1.1 million in Q1-08, compared to NOK 1.6 million and NOK 0.7 million in same quarter 2007. In Q4-07, the operating revenue was NOK 3.3 million and other revenues were NOK 0.8 million. The infectious diseases segment is showing a 26% growth (NOK 2.9 million vs NOK 2.3 million) in sales revenues compared to last quarter. EBITDA in Q1-08 was NOK - 9.4 million compared to NOK - 10.6 million in Q1-07 and NOK - 8.0 million in Q4-07.

Net cash flow in Q1-08 was NOK - 12 million, compared to NOK 28 million in Q1-07 (including proceeds from a private placement of NOK 32 million), and NOK - 10.8 million in Q4-07. Net cash at end of period stands at NOK 24.2 million. The Board of directors stated in the annual report that they are preparing a funding transaction and have engaged a advisor to assist with the transaction which will provide necessary cash for the Company going forward. These plans are progressing as scheduled.

Infectious Diseases
In Q1, NorDiag reached a milestone as the first two instruments were sold to the United Kingdom, and the first instrument was placed in the US. NorDiag is currently in processes with potential partners for strategic collaborations. NorDiag will in May-08 start two clinical trials for STI to prove its sample preparation solutions as an integrated part of Roche`s Taqman 48 and Becton Dickinson`s Probetec system. The trials are expected to take 2-3 months and will be a key element for successful sales development.

Today, the Company has secured rights to a new technology which can be used to develop tests for infectious diseases. The technology is a novel method of genetic engineering to produce purified antigens.

Cancer
The main activity in the Cancer segment this quarter has been to establish a new sample prep for Colorectal Cancer, which has been successfully achieved. Next step is to decide on analytical process/technology based on the markers to be included in the test kit. This work will be concluded during second quarter this year, which implies that the previously announced schedule will be maintained. A continued collaboration with the partners that conducted the clinical study in Germany is discussed, and can lead to the first commercial launch of the new product in Germany before expansion into rest of Europe. Assessments so far indicate a price level for a new test of approximately NOK 400 compared to NOK 2400 for the previous Genefec II test, without compromising on margin targets.

Furthermore, the new collaboration with Exact Sciences is an important step. The collaboration will combine the NorDiag sample prep with Exact`s DIA technology. NorDiag has non- exclusive rights to Exact Science`s DIA test outside US and Canada. The conditions for a successful introduction of a new Genefec III test have also been significantly improved as both American and European regulatory organizations have included gene based testing as an alternative in their guidelines for screening of colorectal cancer.

Complete quarterly report and presentation is attached.

Contact: CEO Mårten Wigstøl Phone. +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 34 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com

Link to the Stock Exchange Notice with report and presentation here

Link to the Stock Exchange Notice in Norwegian here